Therapy News and Research

RSS

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.

18 Apr 2016

UA researchers developing new treatment to delay serious consequences of venomous snakebites

Time is of the essence for treating venomous snakebites, and a product being developed by researchers at the University of Arizona College of Medicine - Tucson may extend that window for treatment.

18 Apr 2016

Existing cancer drugs may be able to help people with enlarged heart cells

UT Southwestern Medical Center cardiology researchers have identified molecular ties between the growth of cancer cells and heart cells that suggest existing cancer drugs may be able to help those with enlarged heart cells -- a condition that can lead to heart attacks and stroke.

18 Apr 2016

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.

18 Apr 2016

Survivin inhibitor with chemotherapy provides therapeutic advantage for Rb cells, tumors

Researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) have demonstrated that targeting survivin - a protein that inhibits apoptosis or cell death - enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children.

18 Apr 2016

Developing countries face health financing crisis due to low domestic investment, stagnating international aid

Two major studies published in The Lancet reveal the health financing crisis facing developing countries as a result of low domestic investment and stagnating international aid, which could leave millions of people without access to even the most basic health services.

18 Apr 2016

Older men receiving testosterone therapy less likely to return to hospital

A new large-scale population-based study from The University of Texas Medical Branch at Galveston showed for the first time that older men using testosterone therapy were less likely to have complications that require them to go back to the hospital within a month of being discharged than men not using this therapy. The study is currently available in Mayo Clinic Proceedings.

16 Apr 2016

New study shows only half of locally advanced rectal cancer patients receive standard therapy

While use of the standard therapy leading to the best outcome against locally advanced rectal cancer has increased over the past decade, only half of patients currently receive it, according to a new study. The authors of the study say the underutilization could be explained in part by socioeconomic factors. The study appears early online in the American Cancer Society's peer-review journal Cancer.

16 Apr 2016

Low-carbohydrate diet helps reduce growth of glioblastoma tumor cells in mouse models

University of Florida Health researchers have slowed a notoriously aggressive type of brain tumor in mouse models by using a low-carbohydrate diet.

16 Apr 2016

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone.

16 Apr 2016

Genetic modification of common virus gives extra weapon to kill cancer cells

A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London.

16 Apr 2016

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Researchers from Massachusetts Eye and Ear/Harvard Medical School have conducted a clinical trial comparing the safety and efficacy of topical tacrolimus, an immunosuppressive therapy, and topical methylprednisolone, a steroid medication, in patients with ocular graft-versus-host-disease (GVHD) -- a complication associated with allogeneic bone marrow transplants in which the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface.

16 Apr 2016

Newly developed implantable device can deliver chemotherapy drugs directly to pancreatic tumors

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, which is located deep within the abdomen.

16 Apr 2016

Willow herb extracts may be beneficial in treating multi-drug resistant bacterial and fungal infections

A common herb could help reduce antibiotic doses and result in less severe side effects in treatments against multi-drug resistant microorganisms.

16 Apr 2016

Study to test effectiveness of worksite exercise regimen to reduce low back injury risk in firefighters

The University of South Florida and Tampa Fire Rescue have launched a randomized controlled trial to assess the effectiveness of a worksite exercise regimen targeted to reduce the risk of low back injury and disability in firefighters -- a physically demanding occupation particularly prone to back problems that can lead to chronic pain and early retirement.

15 Apr 2016

Palovarotene drug may prevent multiple musculoskeletal problems linked with FOP

New research in laboratory animals suggests that the drug palovarotene may prevent multiple skeletal problems caused by a rare but extremely disabling genetic bone disease, and may even be a candidate for use in newborn babies with the condition.

15 Apr 2016

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis.

15 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art medical equipment poses a number of challenges. Inspired by pregnancy tests, researchers from Florida Atlantic University, Stanford University, and Baskent University in Turkey, have developed a novel method to store microfluidic devices for CD4 T cell testing in extreme weather conditions for up to six months without refrigeration.

14 Apr 2016

Therapy News and Research

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

UA researchers developing new treatment to delay serious consequences of venomous snakebites

Existing cancer drugs may be able to help people with enlarged heart cells

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Survivin inhibitor with chemotherapy provides therapeutic advantage for Rb cells, tumors

Developing countries face health financing crisis due to low domestic investment, stagnating international aid

Older men receiving testosterone therapy less likely to return to hospital

New study shows only half of locally advanced rectal cancer patients receive standard therapy

Low-carbohydrate diet helps reduce growth of glioblastoma tumor cells in mouse models

Radiation plus chemotherapy improves survival of low-grade brain cancer patients

Genetic modification of common virus gives extra weapon to kill cancer cells

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Newly developed implantable device can deliver chemotherapy drugs directly to pancreatic tumors

Willow herb extracts may be beneficial in treating multi-drug resistant bacterial and fungal infections

Study to test effectiveness of worksite exercise regimen to reduce low back injury risk in firefighters

Palovarotene drug may prevent multiple musculoskeletal problems linked with FOP

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News